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Do patients at high risk of 
Alzheimer’s disease beneﬁ t 
from early treatment?
Treating early 
Alzheimer’s 
yields statistically 
signiﬁ cant—
though perhaps 
not clinically 
signiﬁ cant—
improvement in 
cognition and 
global function.
Evidence-based answer
Yes, but the extent of the benefi t is 
unclear. Treating patients with early-
stage Alzheimer’s disease yields 
statistically signifi cant, though perhaps 
not clinically signifi cant, improvement in 
cognition and global function (strength 
of recommendation [SOR]: A, consistent 
evidence from multiple randomized 
controlled trials [RCTs]). In a few cases, it 
may delay loss of function and need for 
long-term care. 
 Treating patients with mild cognitive 
impairment (MCI)—the most likely precursor 
to Alzheimer’s disease—with cholinesterase 
inhibitors seems to have an initial, but 
perhaps unsustained, benefi t over no 
treatment (SOR: B, inconsistent results 
from few trials). Withdrawing anticholinergic 
drugs from patients taking them promises 
to reduce symptoms of MCI, but is unlikely 
to reduce rates of Alzheimer’s (SOR: C, 
well-designed observational study).
❚ Evidence summary
Alzheimer’s disease is characterized by 
defi cits in memory and at least 1 other 
cognitive domain (aphrasia, apraxia, ag-
nosia, or loss of executive function) ac-
companied by impaired function. As the 
US population ages, Alzheimer’s disease 
is likely to increase substantially in preva-
Clinical commentary
Remember nondrug interventions
Clinicians often forget the many 
nonpharmacologic treatments for 
dementia, including exercise, cognitive 
stimulation, increased socialization, 
addressing polypharmacy, and optimizing 
nutrition. Diagnosing and managing 
comorbidities such as depression and 
cardiovascular disease are also important. 
Primary care physicians who care for 
the frail elderly should advocate these 
interventions. In the very elderly, who are 
all at high risk of developing Alzheimer’s 
disease, these measures may help prevent 
functional decline and reduce clinically 
apparent disease.
 All patients diagnosed with early-
stage Alzheimer’s disease, and possibly 
patients with MCI, should be offered a 
trial of pharmacotherapy. However—given 
the high cost of drug therapy, the modest 
improvement it produces in patients with 
Alzheimer’s dementia, and the lack of 
defi nitive evidence that it benefi ts patients 
with MCI—I wouldn’t advocate medication 
for asymptomatic patients at high risk of 
developing dementia.
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lence and cost, from its current 4.5 mil-
lion people affected and $100 billion per 
year in direct expenses.1
Because the defi nition of Alzheimer’s 
precludes asymptomatic disease, “early” 
treatment implies either treating a precur-
sor condition or treating before cognitive 
and functional impairment force the pa-
tient and family to seek medical care. The 
literature identifi es 2 possible prodromal 
conditions: MCI and personality change. 
Personality change is proposed as a pro-
drome based only on a small study that 
diagnosed Alzheimer’s disease at autopsy, 
so this Clinical Inquiry doesn’t address it 
further.2
Therapy for MCI: 
A look at 3 interventions
MCI is a measurable memory defi cit, 
more severe than normal aging changes 
(slower learning of new material and 
diffi culty retrieving names and places) 
but not meeting criteria for dementia.3 
Researchers differ on a more precise 
defi nition;  some subdivide MCI into 
“MCI-amnestic type” and “MCI-multiple 
cognitive defi cits type.”4 MCI progresses 
to Alzheimer’s disease in anywhere from 
10% to 56% of patients.4,5 
Three interventions may benefi t pa-
tients with MCI: 
• cholinesterase inhibitors 
• exercise 
•  discontinuation of anticholinergic 
drugs in patients taking them. 
Two recent RCTs of donepezil6,7 
and 1 of galantamine8 showed initial 
cognitive improvement in MCI patients. 
However, the only trial carried out for 
3 years showed no persistent benefi t at 
that time.6 
Another study showed that moderate 
exercise—30 minutes 3 days a week—im-
proves cognition in MCI patients.9 
A longitudinal cohort study found 
that patients taking anticholinergic 
drugs had an 80% prevalence of MCI, 
compared with a 35% prevalence in a 
matched population of patients not us-
ing these drugs; yet Alzheimer’s disease 
hadn’t increased among the anticholiner-
gic drug users at 8-year follow-up. Attrib-
utable risk for MCI from anticholinergic 
drug use was 19%. Stopping anticholin-
ergic medications may reduce the preva-
lence of MCI.10 
In established Alzheimer’s disease, 
cholinesterase inhibitors statistically ben-
efi t patients with early and moderate dis-
ease and probably benefi t patients with 
severe disease.11,12 The treatment effect is 
small, however—3 points on a 70-point 
cognitive scale. Comparison studies show 
mixed results; no single agent appears to 
be most effective.12 
Are cholinesterase inhibitors 
cost effective? 
The relatively modest benefi t of cholin-
esterase inhibitors—especially given their 
expense—has raised questions about cost 
effectiveness. When weighing the choice, 
consider that donepezil may delay nurs-
ing home placement,11,13 and the cholin-
esterase inhibitors may reduce caregiver 
burden.11 The medications are likely to be 
cost effective in patients showing a clini-
cally signifi cant response. More effective 
treatments would clearly be welcome.  
Recommendations
The US Preventive Services Task Force 
(USPSTF) acknowledges that fair to good 
evidence supports a benefi t from treatment 
of early-stage Alzheimer’s disease. Howev-
er, routine screening for dementia in older 
adults receives an I-level recommendation 
(insuffi cient evidence), both because it’s 
unknown whether diagnosis would be as 
accurate and treatment as effective in pri-
mary care practices and because the ben-
efi t from screening is uncertain (coupled 
with a small treatment benefi t).14 
The task force reported fi nding no 
good data that treating MCI is benefi cial. 
However, the USPSTF recommendation 
preceded publication of all 4 RCTs on 
treatment of MCI addressed in this Clini-
cal Inquiry.
The American College of Physi-
cians and American Academy of Family 
For the very 
elderly, encourage 
exercise, cognitive 
stimulation, 
and increased 
socialization, 
which may help 
prevent functional 
decline. 
Physicians published a joint clinical practice 
guideline in March 2008 that questioned 
whether the slight benefi t of cholinesterase 
inhibitors surpassed the harm of adverse ef-
fects and cost. They recommend counseling 
each patient about the likely benefi ts and 
harms.15 ■
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